Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
JD Beebe, JY Liu, JT Zhang - Pharmacology & therapeutics, 2018 - Elsevier
Signal transducer and activator of transcription 3 (STAT3) controls many biological
processes including differentiation, survival, proliferation, and angiogenesis. In normal …
processes including differentiation, survival, proliferation, and angiogenesis. In normal …
Targeting survivin for therapeutic discovery: past, present, and future promises
RC Peery, JY Liu, JT Zhang - Drug discovery today, 2017 - Elsevier
Highlights•Survivin is over-expressed in many cancers and an ideal target for drug
discovery.•Survivin is considered “undruggable” due to lack of known enzymatic …
discovery.•Survivin is considered “undruggable” due to lack of known enzymatic …
Biocatalysis as an alternative for the production of chiral epoxides: a comparative review
Enantiopure epoxides are remarkably versatile intermediates for the synthesis of numerous
biologically active targets, to which considerable efforts have been devoted either …
biologically active targets, to which considerable efforts have been devoted either …
Synthesis of 3-O-sulfonated heparan sulfate octasaccharides that inhibit the herpes simplex virus type 1 host–cell interaction
YP Hu, SY Lin, CY Huang, MML Zulueta, JY Liu… - Nature …, 2011 - nature.com
Cell surface carbohydrates play significant roles in a number of biologically important
processes. Heparan sulfate, for instance, is a ubiquitously distributed polysulfated …
processes. Heparan sulfate, for instance, is a ubiquitously distributed polysulfated …
[HTML][HTML] Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker
Human fatty acid synthase (FASN) is a 270-kDa cytosolic dimeric enzyme that is responsible
for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for …
for palmitate synthesis. FASN is slowly emerging and rediscovered as a marker for …
A small molecule compound targeting STAT3 DNA-binding domain inhibits cancer cell proliferation, migration, and invasion
W Huang, Z Dong, F Wang, H Peng, JY Liu… - ACS chemical …, 2014 - ACS Publications
Signal transducer and activator of transcription 3 (STAT3) plays important roles in multiple
aspects of cancer aggressiveness including migration, invasion, survival, self-renewal …
aspects of cancer aggressiveness including migration, invasion, survival, self-renewal …
Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome
LM Guo, JY Liu, DZ Xu, BS Li, H Han… - Liver …, 2003 - Wiley Online Library
Background: Molecular Adsorbents Recirculating System (MARS) is a new promising
artificial liver support therapy, the aim of this study was to assess the effectiveness of MARS …
artificial liver support therapy, the aim of this study was to assess the effectiveness of MARS …
[HTML][HTML] 14-3-3σ, the double-edged sword of human cancers
Z Li, JY Liu, JT Zhang - American journal of translational research, 2009 - ncbi.nlm.nih.gov
3-3σ is a member of a highly conserved family of 14-3-3 proteins that are present in all
eukaryotic organisms. 14-3-3σ has been considered as a tumor suppressor with reduced …
eukaryotic organisms. 14-3-3σ has been considered as a tumor suppressor with reduced …
FASN regulates cellular response to genotoxic treatments by increasing PARP-1 expression and DNA repair activity via NF-κB and SP1
Fatty acid synthase (FASN), the sole cytosolic mammalian enzyme for de novo lipid
synthesis, is crucial for cancer cell survival and associates with poor prognosis. FASN …
synthesis, is crucial for cancer cell survival and associates with poor prognosis. FASN …
[HTML][HTML] Acute fatty liver of pregnancy: over six months follow-up study of twenty-five patients
HF Xiong, JY Liu, LM Guo, XW Li - World Journal of …, 2015 - ncbi.nlm.nih.gov
AIM: To evaluate the prognosis of patients with acute fatty liver of pregnancy (AFLP) 6 mo or
longer after discharge. METHODS: The records of pregnant patients diagnosed with AFLP at …
longer after discharge. METHODS: The records of pregnant patients diagnosed with AFLP at …